JP2003507327A - 化学化合物 - Google Patents

化学化合物

Info

Publication number
JP2003507327A
JP2003507327A JP2001516533A JP2001516533A JP2003507327A JP 2003507327 A JP2003507327 A JP 2003507327A JP 2001516533 A JP2001516533 A JP 2001516533A JP 2001516533 A JP2001516533 A JP 2001516533A JP 2003507327 A JP2003507327 A JP 2003507327A
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516533A
Other languages
English (en)
Japanese (ja)
Inventor
ハーグレーベス，ロドニー・ブライアン
ホイッタモア，ポール・ロバート・オーウェン
Original Assignee
アストラゼネカ アクチボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アストラゼネカ アクチボラグ filed Critical アストラゼネカ アクチボラグ
Publication of JP2003507327A publication Critical patent/JP2003507327A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2001516533A 1999-08-18 2000-08-14 化学化合物 Pending JP2003507327A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9919411.0 1999-08-18
GBGB9919411.0A GB9919411D0 (en) 1999-08-18 1999-08-18 Chemical compounds
PCT/GB2000/003140 WO2001012187A2 (en) 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists

Publications (1)

Publication Number Publication Date
JP2003507327A true JP2003507327A (ja) 2003-02-25

Family

ID=10859283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516533A Pending JP2003507327A (ja) 1999-08-18 2000-08-14 化学化合物

Country Status (14)

Country Link
EP (1) EP1210343A2 (es)
JP (1) JP2003507327A (es)
KR (1) KR20020020817A (es)
CN (1) CN1379774A (es)
AU (1) AU6583400A (es)
BR (1) BR0013368A (es)
CA (1) CA2380775A1 (es)
GB (1) GB9919411D0 (es)
IL (1) IL147821A0 (es)
MX (1) MXPA02001598A (es)
NO (1) NO20020765L (es)
NZ (1) NZ517059A (es)
WO (1) WO2001012187A2 (es)
ZA (1) ZA200200669B (es)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519196A (ja) * 2003-02-27 2006-08-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体モジュレーターとしての分枝側鎖を有するアリールシクロアルキル誘導体、その製造方法および医薬としてのその使用
JP2008517959A (ja) * 2004-10-27 2008-05-29 エフ．ホフマン−ラ ロシュ アーゲー 新規なインドール又はベンゾイミダゾール誘導体
JP2008535908A (ja) * 2005-04-13 2008-09-04 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
JP2009537472A (ja) * 2006-05-16 2009-10-29 エフ．ホフマン−ラ ロシュ アーゲー １ｈ−インドール−５−イル−ピペラジン−１−イル−メタノン誘導体
JP2017506654A (ja) * 2014-03-20 2017-03-09 ヒュンダイ ファーム カンパニー リミテッド Ｐｐａｒｇに結合するがプロモーターとして作用しない化合物及び有効成分としてそれを含有するｐｐａｒｇ関連疾患を処置するための医薬組成物
JP2020521770A (ja) * 2017-05-26 2020-07-27 南京明徳新薬研発有限公司Ｍｅｄｓｈｉｎｅ Ｄｉｓｃｏｖｅｒｙ Ｉｎｃ． Ｆｘｒ受容体作動薬としてのラクタム系化合物

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495949B1 (en) 1999-11-03 2002-12-17 Orion Electric Co., Ltd. Electron tube cathode
US6503907B2 (en) * 2000-11-28 2003-01-07 Hoffmann-La Roche Inc. Indole and dihydroindole derivatives
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
EP1474385B1 (en) * 2002-02-05 2009-06-10 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
ATE386013T1 (de) 2002-06-20 2008-03-15 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
SE0201937D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
JP2006510673A (ja) 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
AR060451A1 (es) 2006-04-13 2008-06-18 Neuraxon Inc Compuestos de indol 1,5 y 3,6-sustituidos con actividad inhibitoria de nos
US7928238B2 (en) 2006-05-11 2011-04-19 Janssen Pharmaceutica Nv 1,2,3,4-tetrahydro-quinoline derivatives as CETP inhibitors
JP2009536954A (ja) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃｅｔｐ阻害剤としての３，４−ジヒドロ−２ｈ−ベンゾ［１，４］オキサジンおよびチアジン誘導体
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
BRPI0808525A2 (pt) 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
DK2124562T3 (en) 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
BRPI0812851A2 (pt) * 2007-07-02 2014-09-30 Glaxosmithkline Llc Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
FR2921366B1 (fr) * 2007-09-26 2009-12-04 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
KR20100124272A (ko) * 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
MX345040B (es) 2010-11-08 2017-01-16 Albireo Ab Una combinacion farmaceutica que comprende un inhibidor de ibat y un aglutinante de acido biliar.
WO2012170561A1 (en) * 2011-06-06 2012-12-13 The Scripps Research Institute (T.S.R.I.) N-benzylindole modulators of pparg
WO2012170554A1 (en) 2011-06-06 2012-12-13 Theodore Mark Kamenecka N-biphenylmethylindole modulators of pparg
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
CA2860382C (en) 2011-12-21 2017-09-12 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
CN104788358A (zh) * 2014-01-20 2015-07-22 中国科学院上海药物研究所 N-(3-氟-4-氯苄基)吲哚衍生物及其用途
WO2015161108A1 (en) 2014-04-16 2015-10-22 The Scripps Research Institute Pparg modulators for treatment of osteoporosis
CN107176914B (zh) * 2016-03-09 2022-06-28 浙江旭晨医药科技有限公司 新型gvs系列化合物及其用途
WO2020045982A1 (ko) * 2018-08-29 2020-03-05 숙명여자대학교산학협력단 치환된 인돌 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 PPARα, PPARγ 및 PPARδ 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020048547A1 (zh) * 2018-09-07 2020-03-12 南京明德新药研发有限公司 三环并呋喃取代哌啶二酮类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
ES2108641B1 (es) * 1995-07-31 1998-08-16 Menarini Lab Sulfonimidas quinolonicas con accion antagonista de los leucotrienos.
JPH09176162A (ja) * 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
WO1998051667A1 (fr) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Derives d'indole et derives de mono- et diazaindole

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519196A (ja) * 2003-02-27 2006-08-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体モジュレーターとしての分枝側鎖を有するアリールシクロアルキル誘導体、その製造方法および医薬としてのその使用
JP2008517959A (ja) * 2004-10-27 2008-05-29 エフ．ホフマン−ラ ロシュ アーゲー 新規なインドール又はベンゾイミダゾール誘導体
JP2008535908A (ja) * 2005-04-13 2008-09-04 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
JP2015199745A (ja) * 2005-04-13 2015-11-12 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
JP2009537472A (ja) * 2006-05-16 2009-10-29 エフ．ホフマン−ラ ロシュ アーゲー １ｈ−インドール−５−イル−ピペラジン−１−イル−メタノン誘導体
JP2017506654A (ja) * 2014-03-20 2017-03-09 ヒュンダイ ファーム カンパニー リミテッド Ｐｐａｒｇに結合するがプロモーターとして作用しない化合物及び有効成分としてそれを含有するｐｐａｒｇ関連疾患を処置するための医薬組成物
JP2020521770A (ja) * 2017-05-26 2020-07-27 南京明徳新薬研発有限公司Ｍｅｄｓｈｉｎｅ Ｄｉｓｃｏｖｅｒｙ Ｉｎｃ． Ｆｘｒ受容体作動薬としてのラクタム系化合物
US11339147B2 (en) 2017-05-26 2022-05-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Lactam compound as FXR receptor agonist
JP7266538B2 (ja) 2017-05-26 2023-04-28 石薬集団中奇制薬技術（石家庄）有限公司 Ｆｘｒ受容体作動薬としてのラクタム系化合物

Also Published As

Publication number Publication date
NZ517059A (en) 2004-05-28
WO2001012187A2 (en) 2001-02-22
MXPA02001598A (es) 2002-07-02
ZA200200669B (en) 2003-06-25
KR20020020817A (ko) 2002-03-15
CA2380775A1 (en) 2001-02-22
AU6583400A (en) 2001-03-13
CN1379774A (zh) 2002-11-13
IL147821A0 (en) 2002-08-14
NO20020765D0 (no) 2002-02-15
BR0013368A (pt) 2002-05-07
WO2001012187A3 (en) 2001-06-07
NO20020765L (no) 2002-04-17
EP1210343A2 (en) 2002-06-05
GB9919411D0 (en) 1999-10-20

Similar Documents

Publication Publication Date Title
JP2003507327A (ja) 化学化合物
EP2046775B1 (fr) Derives de n- (amino-heteroaryl) - 1h-indole-2 -carboxamides comme antagonistes des recepteurs de type trpv1 ou vr1
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP2022521824A (ja) アンドロゲン受容体の阻害剤を含む薬学的組成物及びその組み合わせならびにその使用
US6787556B1 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
JP5069415B2 (ja) 結晶形態のイミダゾール誘導体
JPH09507216A (ja) ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
IL193279A (en) Piperidinoyl pyrolidines, medicinal preparations containing them and their use in the preparation of medicines
EP3210969B1 (en) Kcnq2-5 channel activator
OA12631A (fr) Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés.
JP4662979B2 (ja) 新規なβ−アゴニスト、その製造方法及びその薬物としての使用
WO2009010560A1 (en) Pyrazole derivatives and use thereof as inhibitors of stearoyl-coa desaturase
WO1992012144A1 (fr) Compose cyclique condense de benzoxa, son procede de production, et composition pharmaceutique le contenant
EP3730509B1 (en) Compound for treating metabolic diseases and preparation method and use thereof
WO2019149089A1 (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
CN102946882A (zh) 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
JP2000309534A (ja) 血管新生阻害剤
JP2005527518A (ja) 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用
WO2002006249A1 (fr) Procede de fabrication d'un derive de 1,2,3 triasol substitue en position 1
CA2557942C (fr) Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique
JPH07507782A (ja) ５−（１，２，４−トリアゾール−１−イルメチル）−３ｈ−イソベンゾフラン−１−オン誘導体，それらの製造およびアロマターゼ阻害剤としての使用
EP1793834B1 (fr) Derives pyridiniques d ' indolin-2-one , leur preparation et leur application en therapeutique
EP3447045B1 (en) 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria
EP1492792B1 (fr) Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino¬4,5-b|indole-1-acetamide,leur preparation et leur application en therapeutique
WO2010066100A1 (zh) 2-氧化-1，3-氧氮杂环戊烷-4-甲酰胺衍生物及其用于制备免疫抑制剂的用途